Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786608 | 0.89 | TSHR (0.34) | TSHR | |
| SCHEMBL1783439 | 0.84 | TSHR (0.35) | TSHR | |
| SCHEMBL7107647 | 0.82 | TSHR (0.39) | TSHR | |
| SCHEMBL21924125 | 0.82 | TSHR (0.39) | TSHR | |
| SCHEMBL1784971 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL1783997 | 0.75 | TSHR (0.32) | TSHR | |
| SCHEMBL1787530 | 0.73 | TSHR (0.35) | TSHR | |
| SCHEMBL1784622 | 0.73 | TSHR (0.52) | TSHR | |
| SCHEMBL27781294 | 0.69 | TSHR (0.40) | TSHR | |
| SCHEMBL4583468 | 0.69 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0404834-A4 | SQUALENE OXIDE CYCLASE INHIBITORS AND THERAPEUTIC USE THEREOF | — | 1991-01-23 | — | — | EP | disclosed |
| EP-0404834-A1 | SQUALENE OXIDE CYCLASE INHIBITORS AND PHARMACEUTICAL COMPOSITION | SOMATOGENETICS INTERNATIONAL, INC. (US) | 1991-01-02 | — | — | EP | disclosed |
| WO-1989008450-A1 | SQUALENE OXIDE CYCLASE INHIBITORS AND THERAPEUTIC USE THEREOF | SOMATOGENETICS INTERNATIONAL, INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| US-4863932-A | Squalene oxide cyclase inhibitors and therapeutic use thereof | SOMATOGENETICS INTERNATIONAL, INC. (US) | 1989-09-05 | — | — | US | disclosed |